N-Glycan Sequencing Kit

PROTEIN TOOLS N-Glycan Sequencing Kit Instruction Manual NEB #E577S 2 reactions Version 1. 1/18 be INSPIRED drive DISCOVERY stay GENUINE

This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals. ISO 91 Registered Quality Management ISO 141 Registered Environmental Management ISO 13485 Registered Medical Devices This product is covered by one or more patents, trademarks and/or copyrights owned or controlled by New England Biolabs, Inc. For more information about commercial rights, please email us at gbd@neb.com. While NEB develops and validates its products for various applications, the use of this product may require the buyer to obtain additional third party intellectual property rights for certain applications. DIONEX and ULTIMATE are registered trademarks of Dionex Corporation. XBRIDGE is a registered trademark of Waters Technology Corporation. LTQ and ORBITRAP are registered trademarks of Thermo Finnigan, LLC Copyright 218, New England Biolabs, Inc.; all rights reserved.

N-Glycan Sequencing Kit Table of Contents: Introduction...2 Protocols...4 Example 1: Characterization of Infliximab Glycans using Exoglycosidase Panel...8 Example 2: Exoglycosidase Combinations to Isolate and Quantitate Potentially Immunogenic Low Abundance Isotopes such as Neu5Gc and a1-3 Galactose in Infliximab, a Murine-derived Therapeutic...1 Example 3: Exoglycosidase Digestion of Enbrel Glycans to Quantitate Overall Level of Fucosylation and High Mannose Structures...12 Frequently Asked Questions...14 Troubleshooting...15 Ordering Information....16 Kit Components Kit components are stored at multiple temperatures. Please store at temperature indicated on each vial. α2-3,6,8,9 Neuraminidase A α2-3 Neuraminidase S α1-3,4,6 Galactosidase β1-4 Galactosidase S β-n-acetylglucosaminidase S α1-2,3,6 Mannosidase α1-2,4,6 Fucosidase O GlycoBuffer 1 (1X) Zinc (1X) 1

Required Materials Not Included Rapid PNGase F (NEB #P71) Fluorophore labeling reaction components: 2-aminobenzamide (2AB) (Sigma A8984) Procainamide (Sigma P9391) Sodium Cyanoborohydride (Sigma 156159) DMSO (Sigma 47231) HILIC columns Acetonitrile (ACN) HPLC/MS Grade 5 mm NH 4 Formate Buffer (ph 4.4) Glacial Acetic Acid HILIC Microspin Column Introduction The N-Glycan Sequencing Kit consists of seven well characterized, highly pure, recombinant exoglycosidase enzymes selected to simplify the process of characterizing typical N-linked glycan structures. The extreme diversity of glycan structures on a glycoprotein makes elucidation of the profile challenging and often a number of orthogonal approaches are employed to verify the individual structures. The use of sequential or tandem exoglycosidase digestion of oligosaccharides followed by mass spectrometry (MS) or capillary electrophoresis (CE) analysis provides detailed carbohydrate sequence information and resolves ambiguities (Figure 1, page 3). The exoglycosidases are all active in a universal buffer system, GlycoBuffer 1, and can be used in single digests or in combination. The kit is compatible with N-linked glycans released from a variety of CHO and murine derived antibodies, as well as N-linked glycans released from other glycoproteins. Optimal incubation times and enzyme concentrations may vary for more complex glycans. The recommended enzyme quantity is sufficient for digestion of up to 13 pmol of released glycans (equivalent to released glycans from approximately 1 µg of antibody) labeled with 2AA, 2AB or procainamide. Other commercially available Instant labels may require a larger quantity of enzyme or a longer incubation time for complete digestion. This protocol describes antibody deglycosylation, glycan labeling, purification and exoglycosidase digestion that can be completed in one day (Figure 2, page 4). The protocol is compatible with subsequent downstream MS and CE analysis. 2

Figure 1: Elucidation of structure associated with Peak 28.83 min (m/z = 14.4) A. Infliximab chimeric antibody 1 14.24 Exoglycosidases are used to resolve assignment of peak with corresponding m/z value of 14.24. α2-3,6,8,9 Neuraminidase A, α1-3,4,6 Galactosidase, and β1-4 Galactosidase S are used to digest the substrate. Disappearance of the peak with β1-4 Galactosidase S indicates the correct structure among the three possible glycoforms. Relative Abundance 95 9 85 8 75 7 65 6 55 5 45 4 35 3 25 2 15 1 5 55.75 61.28 78.7 168.86 191.76 528.73 1192.57 848.85 91.77 1386.57 148.82 4 6 8 1 12 14 16 18 2 m/z 1641.81 1713.7 1813.24 1976.47 A 2 B 8 6 4 2 C 8 8 6 4 Possible structures with m/z at or close to 14 16.94 22.13 18.83 19.72 22.97 24.52 26.7 28.83 3.99 33.85 35.28 36.64 Panel B treated with 2 μl of 16.98 α2-3,6,8,9 Neuraminidase A (NEB #P722) 22.18 19.76 23.2 18.86 28.89 25. 26.15 31.46 32.26 34.5 35.98 16.97 Panel C treated with 1 μl of α1-3,4,6 Galactosidase (NEB #P747) 6 4 2 D 15 17.1 22.19 19.77 23.4 18.87 28.93 25.1 25.58 31.51 32.17 34.5 35.93 Panel D treated with 1 μl of β1-4 Galactosidase S (NEB #P745) 1 5 18.88 19.49 21.87 22.53 24.58 25.93 28.12 29.59 31.43 33.53 34.18 35.78 18 2 22 24 26 28 3 32 34 36 Time (min) Disappearance of peak with β1-4 Galactosidase S allows assignment of glycan isomer Panel A: Total released glycans from Infliximab Panel B: Total released glycans treated with 2 µl α2-3,6,8,9 Neuraminidase A; peak remains Panel C: Total released glycans treated with 1 µl α1-3,4,6 Galactosidase; peak remains Panel D: Total released glycans treated with 1 µl β1-4 Galactosidase S; results in disappearance of peak, verifying the β1-4 galactose linkage of this glycan Gal Glc Man GalNAc GlcNAc Fuc NeuAc NeuGc 3

Figure 2: Glycan sample preparation workflow Deglycosylation 1 minutes PCA or 2AB Labeling 45 minutes HILIC Clean Up 2 minutes Dry Glycans 3 mins-1.5 hrs Exoglycosidase Digestion 3 hours Deglycosylation with Rapid PNGase F Labeling of released glycans by reductive amination or with a fluorophore label HILIC clean-up of labeled glycans Drying of glycans to concentrate and remove volatile solvents Exoglycosidase digestion of labeled glycans Sample ready for downstream analysis or enzyme clean up step if necessary 4 Protocols: Rapid PNGase F Release of Antibody Glycans For optimal heat transfer, use.2 ml thin wall microtubes or alternatively, 1.5 ml centrifuge tubes. A thermal cycler with heated lid, or a microtube heat block, are suitable for incubation. One-step Protocol: 1. Combine up to 1 μg of antibody and H 2 O to a volume of 16 μl. 2. Add 4 μl of Rapid PNGase F Buffer (5X) to make a 2 μl total reaction volume. 3. Add 1 μl of Rapid PNGase F. 4. Incubate 1 minutes at 5 C. Two-step Protocol: Some antibodies (i.e., Fab N-glycans) require a preheating step for efficient deglycosylation. 1. Combine up to 1 μg of antibody and H 2 O to a volume of 16 μl. 2. Add 4 μl of Rapid PNGase F Buffer (5X) to make a 2 μl total reaction volume. 3. Incubate at 8 C for 2 minutes, cool down. 4. Add 1 μl of Rapid PNGase F. 5. Incubate 1 minutes at 5 C.

Fluorescent Labeling with Procainamide (PCA), or 2-aminobenzamide (2AB) 1. Add 18 µl of acidified PCA or 2AB labeling reagent and 24 µl cyanoborohydride reagent to the deglycosylation reaction and incubate for 45 minutes at 65 C. Note: Stock solutions can be made fresh or kept at -2 C and thawed prior to use (reagents remain stable for several weeks and through numerous freeze/thaw cycles). Reagents prepared as follows: PCA (55 mg dissolved in 1 ml DMSO), 2AB (25 mg dissolved in 1 ml DMSO), and sodium cyanoborohydride (2 mg/ml in H 2 O). Prepare acidified PCA or 2AB solution by adding one volume of glacial acetic acid to eight volumes of PCA or 2AB stock solution. 2. Cool reactions to room temperature. Glycan Purification with a HILIC Spin Column Released, labeled glycans can be purified from the free label using various methods. Purified glycans must be free of organic solvents prior to enzyme digestion. 1. Add 35 µl Acetonitrile (ACN) to the labelled reactions to a final concentration of 85% ACN. 2. Using either a vacuum manifold or centrifuge adapter (following manufacturer s instructions), condition a HILIC spin column with 35 µl H 2 O, followed by 35 µl of 5 mm ammonium formate, ph 4.5. 3. Equilibrate column with 35 µl of 85% ACN/15% ammonium formate. 4. Load sample onto the HILIC column, spin. 5. Wash column with 3 µl of 1% formic acid, 9% ACN, repeat 5 times. 6. Elute glycans into a fresh collection tube with 3 µl of 5 mm ammonium formate, ph 4.4. Repeat 3 times for a final volume of 9 µl. 7. Dry the 9 µl glycan sample in a speed vac with temperature no greater than 4 C or lyophilize overnight Note: To minimize drying time, samples can be aliquoted into several tubes prior to placing in speed vac. 8. Resuspend the sample in 1 µl H 2 O for subsequent exoglycosidase digestion reactions. The resuspension volume can be modified to accommodate subsequent exoglycosidase reactions. 5

Exoglycosidase Digestion of Labelled Glycans Exoglycosidase reactions can be assembled with single or multiple enzymes. The amount of labeled glycan should be determined based on the downstream method of analysis (i.e., HPLC, UPLC, MS, CE). Considerations include the instrument range of detection and the signal to noise ratio of the fluorophore used. This protocol allows for the digestion of up to 13 pmol (equivalent to 1 µg of antibody) using the recommended amounts of exoglycosidase(s). 1. Combine up to 13 pmol of labeled, purified glycans (1 µg antibody) and H 2 O to a total reaction volume of 2 µl. Note: Labeled glycans can be increased to a maximum of 33 pmol (25 µg of antibody) using the recommended amount of exoglycosidases with an incubation time of 18 hr at 37 C. 2. Add 2 µl of 1X GlycoBuffer 1. 3. Add the recommended volume of each exoglycosidase (single or in combination) to yield the specific structures, as shown in Table 1. 4. Incubate reactions for 3 hours at 37 C. Note: If digestion is not complete, increase incubation time to 18 hours at 37 C. Samples can be analyzed directly with MS or CE or can be further purified to remove enzymes from the reactions if necessary. 6

Table 1: Exoglycosidase Digestion Panel EXOGLYCOSIDASES RXN 1 RXN 2 RXN 3 RXN 4 RXN 5 RXN 6 RXN 7 α2-3 Neuraminidase S (NEB #P743) 1 µl α2-3,6,8,9 Neuraminidase A (NEB #P722) 2 µl 2 µl 2 µl 2 µl 2 µl α1-3,4,6 Galactosidase (NEB #P747) 1 µl 1 µl 1 µl 1 µl β1-4 Galactosidase S (NEB #P745) 1 µl 1 µl 1 µl β-n- Acetylglucosaminidase S (NEB #P744) 1 µl 1 µl α1-2,3,6 Mannosidase* (NEB #P768) 2 µl α1-2,4,6 Fucosidase O (NEB #P749) 2 µl Glycan Product *Supplement reaction with final reaction concentration of 1X Zinc for optimal activity. Gal Glc Man GalNAc GlcNAc Fuc NeuAc NeuGc 7

Example 1: Characterization of Infliximab Glycans using Exoglycosidase Panel Infliximab (3 µg) was deglycosylated with Rapid PNGase F, released glycans were labeled with procainamide (PCA) and purified as described in the general protocol. PCA-labeled glycans were lyophilized and resuspended in 3 µl of water. 1. Prepare exoglycosidase reactions as described in Table 2: Table 2: Exoglycosidase Digestion Panel COMPONENT RXN 1 RXN 2 RXN 3 RXN 4 RXN 5 RXN 6 N-glycans-PCA Labelled 5 µl 5 µl 5 µl 5 µl 5 µl 5 µl GlycoBuffer 1 (1X) 2 µl 2 µl 2 µl 2 µl 2 µl 2 µl H 2 O 13 µl 11 µl 1 µl 9 µl 8 µl 6 µl α2-3,6,8,9 Neuraminidase A (NEB #P722) 2 µl 2 µl 2 µl 2 µl 2 µl α1-3,4,6 Galactosidase (NEB #P747) 1 µl 1 µl 1 µl 1 µl β1-4 Galactosidase S (NEB #P745) 1 µl 1 µl 1 µl β-n-acetylglucosaminidase S (NEB #P744) 1 µl 1 µl α1-2,4,6 Fucosidase O (NEB #P749) 2 µl Total 2 µl 2 µl 2 µl 2 µl 2 µl 2 µl 2. Incubate samples for 3 hours at 37 C 3. Add 1 μl of 5 mm NH 4 formate buffer ph 4.4 and 9 μl acetonitrile to each reaction for a final acetonitrile concentration of 7%. 4. Analyze by LCMS, results shown in Figure 3A and 3B: N-glycan samples are separated using a XBridge BEH Amide column (Waters) on a Dionex UltiMate LC equipped with fluorescent detection in line with a LTQ Orbitrap Velos Spectrometer equipped with a heated electrospray standard source (HESI-II probe). 8

Figure 3A: N-Glycans released from Infliximab, labeled with PCA, digested for 3 hours with exoglycosidases. See figure 3B below 16.94 Total glycan profile 5 rxn 1 5 rxn 2 7.98 9.92 7.94 9.92 22.13 22.97 18.83 14.3 28.83 14.63 19.72 3.99 36.64 24.52 26.7 33.85 11.86 35.28 16.98 22.18 19.76 23.2 14.7 14.67 28.89 18.86 25. 26.15 34.5 11.9 31.46 32.26 37.17 α2-3,6,8,9 Neuraminidase A (NEB #P722) rxn 3 5 15 1 rxn 4 5 1 rxn 5 15 1 5 rxn 6 7.91 16.97 22.19 14.4 19.77 23.4 28.93 9.87 11.87 14.64 18.87 25.1 31.51 34.5 35.93 17.1 14.9 7.93 9.94 11.92 14.68 18.88 21.87 24.58 25.93 28.12 29.92 31.43 34.18 35.78 11.4 18.86 9.35 15.48 16.34 21.51 28.12 28.92 31.37 34.9 13.18 22.63 24.71 26.31 35.73 37.54 9.41 18.88 1.4 13.21 14.12 16.79 26.36 24.68 28.8 3.86 32.2 23.94 34.99 8.2 19.7 35.81 1 15 2 25 3 35 37.55 37.5 37.49 α2-3,6,8,9 Neuraminidase A (NEB #P722) α1-3,4,6 Galactosidase (NEB #P747) α2-3,6,8,9 Neuraminidase A (NEB #P722) α1-3,4,6 Galactosidase (NEB #P747) β1-4 Galactosidase S (NEB #P745) α2-3,6,8,9 Neuraminidase A (NEB #P722) α1-3,4,6 Galactosidase (NEB #P747) β1-4 Galactosidase S (NEB #P745) β-n-acetylglucosaminidase S (NEB #P744) α2-3,6,8,9 Neuraminidase A (NEB #P722) α1-3,4,6 Galactosidase (NEB #P747) β1-4 Galactosidase S (NEB #P745) β-n-acetylglucosaminidase S (NEB #P744) α1-2,4,6 Fucosidase O (NEB #P749) Digestion of Infliximab with a sequential panel of exoglycosidases serves as a tool to elucidate and verify glycan profile. Refer to Table 2 for reaction conditions. Figure 3B: Expanded lower abundance profile of Infliximab glycan analysis Region enlarged to see lower abundance glycans. Digestion with α2-3,6,8,9 Neuraminidase A and α1-3,4,6 Galactosidase facilitates assignment of low abundance, complex glycans. 12 22.97 1 8 6 4 28.83 3.99 36.64 rxn 1 2 24.52 24.94 26.7 33.25 27.77 29.45 35.28 33.85 37.57 38.32 35.97 39.41 23.2 12 1 8 6 28.89 α2-3,6,8,9 Neuraminidase A (NEB #P722) rxn 2 4 2 25. 31.46 34.5 24.57 26.15 29.44 35.98 37.17 27.77 32.26 37.49 39.22 12 23.4 rxn 3 1 8 6 4 2 24.63 25.1 28.93 31.51 32.11 29.62 34.5 25.58 35.93 26.68 37.55 39.4 24 26 28 3 32 34 36 38 4 α2-3,6,8,9 Neuraminidase A (NEB #P722) α1-3,4,6 Galactosidase (NEB #P747) Time (min) Gal Glc Man GalNAc GlcNAc Fuc NeuAc NeuGc 9

Example 2: Exoglycosidase Combinations to Isolate and Quantitate Potentially Immunogenic Low Abundance Isotopes such as Neu5Gc and α1-3 Galactose in Infliximab, a Murine-derived Therapeutic Using combinations of enzymes can be useful to simplify the glycan profile data and isolate a species of interest. Glycans were released from 15 µg of Infliximab using Rapid PNGase F and labelled with procainamide (PCA). Purified, labelled glycans were resuspended in 15 µl of H 2 O. 1. Prepare exoglycosidase reactions as described in Table 3: Table 3: Exoglycosidase Digestion Panel COMPONENT RXN A RXN B RXN C N-glycans-PCA Labelled 5 µl 5 µl 5 µl GlycoBuffer 1 (1X) 2 µl 2 µl 2 µl H 2 O 13 µl 8 µl 7 µl α2-3,6,8,9 Neuraminidase A (NEB #P722) 2 µl α1-3,4,6 Galactosidase (NEB #P747) 1 µl β1-4 Galactosidase S (NEB #P745) 2 µl 2 µl β-n-acetylglucosaminidase S (NEB #P744) 2 µl 2 µl Total 2 µl 2 µl 2 µl 2. Incubate samples for 3 hours at 37 C 3. Add 1 μl of 5 mm NH 4 formate buffer ph 4.4 and 9 µl acetonitrile to each reaction for a final acetonitrile concentration of 7%. 4. Analyze by LCMS, results shown in Figure 4: N-glycan samples are separated using a XBridge BEH Amide column (Waters) on a Dionex UltiMate LC equipped with fluorescent detection in line with a LTQ Orbitrap Velos Spectrometer equipped with a heated electrospray standard source (HESI-II probe). 1

Figure 4: Enzyme combinations help isolate and quantitate potentially immunogenic low abundance isotopes such as Neu5Gc and α1-3 Galactose in Infliximab, a murine-derived therapeutic. A 35 3 17.7 25 2 15 22.22 Total glycan profile 1 5 23.6 28.87 19.85 18.98 3.84 36.57 33.69 35.2 37.52 25.2 26.19 39.32 B 3 19.5 3.94 25 2 Following digestion, Neu5Gc epitopes are easily quantitated 15 1 21.7 35.26 37.56 5 16.57 3.16 27.78 16.93 19.6 22.68 24.84 27.52 33.39 39.36 C 3 25 19.7 2 15 1 21.72 24.97 Following digestion, α1-3 Galactose epitopes are easily quantitated 5 16.55 26.31 36.5 37.23 34.66 32.2 16.87 26.67 19.72 22.16 28.92 37.53 18 2 22 24 26 28 3 32 34 36 38 4 Time (min) RXN A: Total glycan profile. RXN B: Infliximab glycan digestion with 1 μl of α1-3,4,6 Galactosidase, 1 μl of β1-4 Galactosidase S, and 1 μl of β-n-acetylglucosaminidase S. RXN C: Infliximab glycan digestion with 2 μl of α2-3,6,8,9 Neuraminidase A, 1 μl of β1-4 Galactosidase S, and 1 μl of β-n-acetylglucosaminidase S. Gal Glc Man GalNAc GlcNAc Fuc NeuAc NeuGc 11

Example 3: Exoglycosidase Digestion of Enbrel Glycans to Quantitate Overall Level of Fucosylation and High Mannose Structures Glycans were released from 15 µg of Enbrel using Rapid PNGase F and labelled with procainamide (PCA) as described in the general protocol. Purified, labelled glycans were resuspended in 15 µl of H 2. 1. Prepare exoglycosidase reactions as described in Table 4: Table 4: Exoglycosidase Digestion Panel COMPONENT RXN A RXN B RXN C N-glycans-PCA Labelled 5 µl 5 µl 5 µl GlycoBuffer 1 (1X) 2 µl 2 µl 2 µl H 2 O 13 µl 8 µl 6 µl α2-3,6,8,9 Neuraminidase A (NEB #P722) 2 µl 2 µl β1-4 Galactosidase S (NEB #P745) 2 µl 2 µl β-n-acetylglucosaminidase S (NEB #P744) 1 µl 1 µl α1-2,4,6 Fucosidase O (NEB #P749) 2 µl Total 2 µl 2 µl 2 µl 2. Incubate samples for 3 hours at 37 C 3. Add 1 μl of 5 mm NH 4 formate buffer ph 4.4 and 9 µl acetonitrile to each reaction for a final acetonitrile concentration of 7%. 4. Analyze by LCMS, results shown in Figure 5: N-glycan samples are separated using a XBridge BEH Amide column (Waters) on a Dionex UltiMate LC equipped with fluorescent detection in line with a LTQ Orbitrap Velos Spectrometer equipped with a heated electrospray standard source (HESI-II probe). 12

Figure 5: Glycans released from Enbrel, trimmed to the trimannosyl core with exoglycosidases to quantitate overall level of fucosylation and high mannose structures. A 25 2 17.14 34. 36.36 15 1 22.38 31.57 5 1.1 14.26 23.22 29.1 35.37 19.6 28.54 14.8 26.24 19.81 38.53 B 1 8 6 4 9.56 11.46 Following digestion, high mannose and fucosylated epitopes are easily quantitated 2 C 9.56 13.65 15.54 18.95 21.64 25.4 27.68 29.67 31.41 35.25 39.31 12 1 8 6 Fucose residues are removed with α1-2,4,6 Fucosidase O 4 2 11.59 13.25 16.21 18.96 22.6 24.83 28.9 3.4 31.41 35.26 39.5 1 15 2 25 3 35 Time (min) RXN A: Total glycan profile. RXN B: Enbrel glycan digestion with 2 μl of α2-3,6,8,9 Neuraminidase A, 1 μl of β1-4 Galactosidase S, and 1 μl of β-n-acetylglucosaminidase S. RXN C: Enbrel glycan digestion with 2 μl of α2-3,6,8,9 Neuraminidase A, 1 μl of β1-4 Galactosidase S, 1 μl of β-n-acetylglucosaminidase S, and 2 μl of α1-2,4,6 Fucosidase O. Gal Glc Man GalNAc GlcNAc Fuc NeuAc NeuGc 13

14 Frequently Asked Questions (FAQs) Is this protocol suitable for digestion of glycoproteins? Although this protocol has been optimized for digestion of antibodies, it can be utilized with various other glycoproteins. Some glycoproteins are not efficiently deglycosylated with Rapid PNGase F. In this case, the glycoprotein can be treated with PNGase F Glycerol-free, Recombinant (NEB #P79) using denaturing reaction conditions. How do I calculate the molarity of released glycans from my antibody substrate? Typically an IgG antibody with Fc glycosylation has approximately 13.3 pmol of glycans per 1 µg of antibody. Why are two different neuraminidase enzymes provided? α2-3,6,8,9 Neuraminidase A (NEB #P722) has a broader specificity, as it cleaves both α2-3,6,8,9 linked Neu5Ac (N-Acetylneuraminic acid) and Neu5Gc (N-Glycolylneuraminic acid) residues. Neu5Gc epitopes are found in murine derived antibodies. α2-3 Neuraminidase S (NEB #P743) cleaves only α2-3 linked Neu5Ac residues. Should I use the One- or Two-step Rapid PNGase F deglycosylation method for my antibody? Rapid PNGase F has been developed for efficient and fast deglycosylation of antibodies in a simple One-step reaction at 5 C. However, some IgGs (i.e., carrying Fab glycosylation) require a pre-denaturing step of 2 minutes at 8 C. We recommend starting with the standard One-step protocol. If there is evidence (i.e., by gel migration or proteomic analysis) that N-glycans remain attached to the protein, follow the Two-step protocol. The deglycosylation protocol is recommended for up to 1 µg of antibody; How do I determine the amount of starting material I should deglycosylate? There are several factors to consider. In general, the substrate is prepared in batch and then subdivided for enzyme digestion; therefore the number of final exoglycosidase reactions desired needs to be determined. Furthermore, the sensitivity of the particular fluorescent label used determines the quantity of labelled glycan required for adequate signal detection. Some instant labels, such as Rapifluor, have a sensitive fluorescent detection and good signal intensity for mass detection and so less starting material is required. Is it possible to combine the a1-2,3,6 Mannosidase with other exoglycosidases? Are any of the exoglycosidases inhibited by the zinc that is required for optimal mannosidase activity? Yes, a1-2,3,6 Mannosidase (NEB #P768) can be combined with any of the exoglycosidases provided; 1X Zinc will not affect the activity of the other enzymes.

Does ammonium formate inhibit exoglycosidase digestion? Yes, the exoglycosidases are sensitive to ammonium formate, it is important that no ammonium formate remains after elution. If necessary, dry the sample in a speed vac or lyophilize and resuspend in water prior to exoglycosidase digestion. How long do I need to incubate a Rapifluor labelled substrate with the exoglycosidases? Rapifluor-labelled glycans released from 1 µg or less of antibody are fully digested in 3 hrs with a2-3,6,8,9 Neuraminidase A, a1-3,4,6 Galactosidase, b1-4 Galactosidase S, b-n-acetylglucosaminidase S and a1-2,3,6 Mannosidase. However, a1-2,4,6 Fucosidase O requires an 18 hour incubation at 37 C for complete digestion. Which is the enzyme of choice to release a1-6 fucose residues from antibody glycans: a1-2,4,6 Fucosidase O or a1-2,3,4,6 Fucosidase from bovine kidney? a1-2,4,6 Fucosidase O cleaves a1-6 fucose residues from antibody glycans more effectively than a1-2,3,4,6 Fucosidase from bovine kidney. a1-2,4,6 Fucosidase O does require an 18 hour incubation at 37 C for complete digestion. Troubleshooting Incomplete Digestion of Glycans with Exoglycosidases Be sure glycans are fully dried after speed vac or lyophilization step. Residual ACN can inhibit activity of exoglycosidases Increase incubation time of exoglycosidase reactions to 18 hours at 37 C if shorter incubation was performed Low Fluorescent or Mass Spec Signal Increase the amount of labelled glycans used in the digestions. Concentrate sample if necessary Make fresh 1% formic acid, 9% ACN wash solution, if solution becomes more aqueous, the glycans can elute in the wash step 15

Ordering Information PRODUCT NEB # SIZE N-Glycan Sequencing Kit E577S 2 reactions KIT COMPONENTS SOLD SEPARATELY a2-3,6,8,9 Neuraminidase A P722S/L 8/4, units a2-3 Neuraminidase S P743S/L 4/2, units a1-3,4,6 Galactosidase P747S/L 2/1, units b1-4 Galactosidase S P745S/L 4/2, units b-n-acetylglucosaminidase P744S/L 1/5 units a1-2,3,6 Mannosidase P768S/L 8/4 units a1-2,4,6 Fucosidase O P749S/L 8/4 units 16

USA New England Biolabs, Inc. 24 County Road Ipswich, MA 1938-2723 Telephone: (978) 927-554 Toll Free: (USA Orders) 1-8-632-5227 Toll Free: (USA Tech) 1-8-632-7799 Fax: (978) 921-135 e-mail: info@neb.com www.neb.com CANADA New England Biolabs, Ltd. Telephone: (95) 665-4632 Toll Free: 1-8-387-195 Fax: (95) 665-4635 Fax Toll Free: 1-8-563-3789 e-mail: info.ca@neb.com www.neb.ca CHINA New England Biolabs (Beijing), Ltd. Telephone: 1-82378265/82378266 Fax: 1-82378262 e-mail: info@neb-china.com www.neb-china.com FRANCE New England Biolabs France Free Call: 8-1-632 Free Fax: 8-1-61 e-mail: info.fr@neb.com www.neb-online.fr GERMANY & AUSTRIA New England Biolabs GmbH Telephone: +49/()69/35 2314 Free Call: 8/246 5227 (Germany) Free Call: 8/246 52277 (Austria) Fax: +49/()69/35 23149 Free Fax: 8/246 5229 (Germany) e-mail: info.de@neb.com www.neb-online.de JAPAN New England Biolabs Japan, Inc. Telephone: +81 ()3 5669 6191 Fax: +81 ()3 5669 6192 e-mail: info.jp@neb.com www.nebj.jp SINGAPORE New England Biolabs Pte. Ltd. Telephone: +65 638 59623 Fax: +65 638 59617 e-mail: sales.sg@neb.com www.neb.sg UNITED KINGDOM New England Biolabs (UK) Ltd. Telephone: (1462) 42616 Call Free: 8 318486 Fax: (1462) 42157 Fax Free: 8 435682 e-mail: info.uk@neb.com www.neb.uk.com